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Osteoporosis increases fracture risk, especially in metaphyseal bone. Fractures seriously impair function and quality of
life and incur large direct and indirect costs. Although the prevention of fractures is certainly the option, a fast and
uneventful healing process is optimal when fractures do occur. Many new therapeutic strategies have been developed to
accelerate fracture-healing or to diminish the complication rate during the course of fracture-healing. However, widely
accepted guidelines are needed to demonstrate the positive or negative interactions of bioactive substances, drugs, and
other agents that are being used to promote fracture-healing. For each study design, the primary study goal should be
indicated. Outcome variables should include both objective and subjective parameters. The guidelines should be har-
monized between European and American regulatory authorities to ensure comparability of results of studies and to
foster global harmonization of regulatory requirements.
Quality of Life After Fractures
F
ractures greatly impair the quality of life of the affected
individual. Although adequate surgical treatment might
restore full function and quality of life, there remains a
finite risk of permanent deficit as well as the risk of a com-
plication during the course of healing1,2. The risk of permanent
deficits or complications depends on fracture characteristics,
patient-related risk factors, and treatment-specific complica-
tions3-7. Complications have direct consequences for the pa-
tient and also have serious socioeconomic impact. A prolonged
rehabilitation process and a delayed return to work, the need
for salvage procedures, or a permanent need for care will all
require additional resources.
Osteoporosis greatly aggravates the problems mentioned
above. It increases the risk of fracture8, especially in meta-
physeal regions; it impairs function and quality of life9; and it
causes marked direct and indirect costs10-12. An impaired ability
to walk after a hip fracture or a decrease in grip strength after a
radial fracture are examples of a possible loss of independence,
the need for additional care, and increased costs13-15.
Although the prevention of fractures is certainly the goal,
a fast and uneventful healing process is optimal when fractures
do occur. Many new therapeutic strategies have been developed
to accelerate fracture-healing or to diminish the complication
rate during the course of fracture-healing16,17. Existing treatment
protocols have provided evidence that some approaches can
influence fracture-healing18. However, widely accepted guide-
lines are needed to demonstrate the positive or negative inter-
actions of the bioactive substances, drugs, and other agents that
are being used to promote fracture-healing in clinical trials.
Potential Targets for Drugs
Fracture-Healing
Fracture repair involves different stages of tissue differenti-ation, certain aspects of which resemble embryological
skeletal development. The initial injury provokes an inflam-
matory response, followed by a periosteal response and en-
dochondral bone formation. Cartilage resorption and woven
bone formation are the next steps. The final stage of fracture
repair is secondary bone formation through coupled remod-
eling19. The duration of the different phases greatly varies,
depending on location, characteristics of the fracture, patient-
related risk factors, and treatment. Diaphyseal fracture-healing
and metaphyseal fracture-healing demonstrate substantial bio-
mechanical, histological, and radiographic differences that can
challenge the investigator.
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Several drugs and other active substances have been
shown to interact with these processes during fracture-
healing18,20. Growth factors other than bone morphogenetic pro-
teins (BMPs) are expressed during fracture repair, and these
growth factors have been applied with or without a carrier with
successful results in animal models but not in humans21-25.
Bone morphogenetic proteins are part of a complex
signaling system consisting of several BMP molecules, different
receptors, and soluble antagonists. BMPs also induce osteo-
clastic bone resorption, and this response often comes before
the bone formative response26,27. It has therefore been suggested
that, in some situations, BMP treatment could be comple-
mented with a bisphosphonate to provide protection from
bone resorption28, but the possible anabolic, synergistic effect
of these two drugs will have to be verified in vivo. BMP sig-
naling and the response to BMPs are both dependent on me-
chanical loading29,30. BMPs stimulate fracture repair effectively
in most animal models, but the need to apply massive doses of
the protein is a problem. Two types of BMPs are currently
approved for the treatment of fractures. In addition, parathy-
roid hormone has also been shown to stimulate fracture repair
in rats31,32; however, the most dramatic effects come late in the
process, after bridging bone has been developed33.
There are at least four different receptors for prosta-
glandin E2, with separate distribution and separate second
messenger systems. Selective agonists for the receptors EP2 and
EP4 have been shown to stimulate fracture repair in rodent
and dog models34,35.
Statins can activate the promoter of the BMP-2 gene and
improve bone formation in rats36 and fracture repair in mice37.
So far, no data are available that prove this effect in other spe-
cies or in humans.
Bone mass is also regulated from the hypothalamus by
way of the adrenergic system. In consequence, propranolol, a
common beta-blocker, increases bone mass in wild-type mice38
and enhances the repair of bone defects in rats39.
Rather than relying solely on the stimulation of bone
formation, it is also possible to inhibit resorption with the use
of bisphosphonates, leading to a net anabolic effect that en-
hances repair40.
Fracture Fixation
Several biomechanical tests have shown that pull-out or shear
strength and other characteristic variables of fixation correlate
with the amount or structure of bone that surrounds the fix-
ation device. Pull-out and shear tests of single screws have
revealed that there is a linear correlation between both of these
loading modes and bone mineral density as well as cortical
thickness along screws41. Limited cyclic testing of experimental
spinal implants showed that subsidence under perpendicular
loading correlates best (inversely) with the mean space between
trabeculae, which corresponds with trabecular separation42.
Dayer et al., using micro-computed tomography measure-
ment, found that pull-out of titanium rods correlates with
bone-to-implant contact43. Thus, drugs or treatment regimens
that have an effect on bone remodeling are also likely to in-
fluence the quality of fixation. This theory has been proven in
animal experiments43-46 as well as in humans47-49. Just as bone
formation can be enhanced with the use of anabolic drugs50,51,
fixation can be improved with the use of bisphosphonates to
inhibit resorption52. Bisphosphonates can be applied easily to
hydroxyapatite53 or linked to metal surfaces, and these methods
have been shown to improve mechanical fixation of metal
screws in bone in animal models47,54.
Current Regulatory Status
There is currently no European regulatory guidance forclinical evaluation of pharmacologic therapies intended to
augment the fracture-healing process. However, two products
have been approved by the European Medicines Agency
(EMEA), which provides information and experience to aid
future guidance development. The primary outcomes for these
product studies were different and included a radiographic end
point, the complication rate, or a composite of radiographic,
functional, and complication rates.
One approved product is InductOs recombinant human
(rh)BMP-2 (Wyeth Pharmaceuticals, Madison, New Jersey),
which is indicated for use in the specific situation of ‘‘single
level between L4 and S1 anterior lumbar spine fusion as a sub-
stitute for autogenous bone graft in adults with degenerative
disc disease who have had at least six months of nonoperative
treatment for this condition.’’55 It is also indicated ‘‘for the treat-
ment of acute tibial fractures in adults as an adjunct to stan-
dard care using open fracture reduction and intramedullary
(IM) nail fixation.’’55 The two indications were granted on the
basis of successful conduct in studies of the specific fractures.
For the indication for use during spinal fusion, the
primary efficacy variable was spinal fusion measured by in-
dependent radiographic reviewers. Pain and disability status
was also measured by the subjects with use of the Oswestry
Low Back Pain Disability Index Questionnaire56. The study
included 279 men and women who were older than eighteen
years of age and who had degenerative disc disease and one or
more of the following: (1) instability, (2) osteophyte forma-
tion, (3) decreased disc height, (4) thickening of the liga-
mentous tissue, (5) disc degeneration or herniation, and/or (6)
facet joint degeneration. Subjects were required to have a base-
line Oswestry score of 35 or greater, no greater than grade-1
spondylolisthesis, single-level symptomatic degenerative in-
volvement from L4 to S1, and no response to six months of
nonoperative treatment57.
For the indication for use in the treatment of acute tibial
fracture, the primary efficacy variable was the proportion of pa-
tients requiring a secondary intervention to promote fracture-
healing within twelve months of definitive wound closure. The
study included 450 patients with open tibial shaft fractures that
required surgical management including use of an intramed-
ullary nail. Patients at all levels of fracture severity were in-
cluded; only those at high risk of amputation (Gustilo-Anderson
type IIIC58,59) were excluded60.
The other product that has received marketing approval
in Europe is Osigraft recombinant human osteogenic protein-1
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(rhOP-1) or BMP-7 (Stryker Biotech, Hopkinton, Massachu-
setts), which is indicated for ‘‘the treatment of nonunion of the
tibia of at least 9 month duration, secondary to trauma in
skeletally mature patients, in cases where previous treatment
with autograft has failed or use of autograft is unfeasible.’’61
In the study of this product, 122 patients with nonunion
of the tibia treated with Osigraft or autograft were included62.
For demonstration of efficacy, the protocol required all of the
following criteria to be demonstrated by nine months: (1)
evidence of cortical and/or trabecular bridging of the non-
union gap in three of four radiographic views or bridging of
three or more cortices, (2) full weight-bearing in the affected
limb, (3) patient not suffering from severe pain in the affected
limb, (4) no surgical intervention at the nonunion site with the
intention of promoting healing, and (5) absence of chronic
donor-site pain. Patient outcomes were assessed with use of a
visual analog scale and the Short Form-36 physical functioning
indices.
Each of these treatments includes both a growth factor
and an implantable device intended to permit local delivery. In
the European Union, the products were reviewed and ap-
proved by the EMEA Committee for Medicinal Products for
Human Use (CHMP) as medicinal products because the
principal action of the products is pharmacologic63. In con-
trast, the review and approval of InductOs was the responsi-
bility of the Center for Devices and Radiological Health at the
United States Food and Drug Administration (FDA).
Requirements for New Regulatory Guidance
Investigators, sponsors, and participating centers of clinicalstudies should make certain that any trials testing new
substances with proposed effects on fracture-healing will be
accepted by the regulatory authorities (both the FDA and the
EMEA). Additionally, the outcome of the study should be of
substantial interest and medical relevance to the scientific
community and, last but not least, relevant for the patient. It
will be of substantial value to develop harmonized guidelines
for any new locally applied as well as systemic treatments that
become available for testing in patients with fractures.
On the basis of the characteristics of fracture-healing and
fixation, two separate study goals are appropriate—the re-
duction of fracture-healing complications, and the acceleration
of fracture-healing. The intended goal should then determine
subsequent study methodology. Whereas the approach to
studying spinal fusion requires the staging of fracture-healing
at defined points as well as precise definitions of expected
complications, the approach to studying tibial fracture requires
repeated measures of fracture-healing. The second approach is
more complex because definitive methods for monitoring
fracture-healing have not yet been established.
Radiographic evaluation of fracture-healing incorpo-
rates several parameters, including the assessment of the dis-
appearance of fracture lines and the presence of cortical
bridging as well as a determination of the diameter and shape
of the callus. Radiographic scoring of fracture-healing has
largely relied on investigator assessment, and currently there
are no in vivo techniques to quantify healing in mechanical
terms for fractures involving mainly trabecular bone. Further
validation of radiographic scoring should be undertaken, and
semiautomated methods are required64. Radiographic evalua-
tion may occur at multiple time-points during the healing
process, with the aim of measuring the time taken to reach a
defined status (e.g., cortical bridging), or may occur at a single
predetermined time-point at which patients reach a common
clinical milestone (e.g., pain-free loading). Newer imaging
techniques, such as computed tomography, may enhance the
ability to assess fracture-healing65. Radiostereometric analysis
was introduced as a way of measuring the increase in stiffness
during fracture-healing and has the potential to monitor
fracture-healing in vivo66; however, use of this method in large
clinical trials is not yet feasible.
In addition to objective outcome parameters, the equally
important parameter of patient self-assessment should be in-
corporated in clinical studies on fracture-healing. Patient re-
sponses to questions regarding function and quality of life help
to quantify relevant therapeutic effects for individuals as well
as for groups of patients67. The parameter of self-assessment
should also correspond to the holistic International Classifi-
cation of Functioning, Disability and Health (ICF) approach of
the World Health Organization through the inclusion of
questions that evaluate how the disability (e.g., a distal radial
fracture) affects different levels of interpersonal interaction68. If
we can assume that return of function (to a certain extent)
parallels fracture-healing, then we can utilize self-assessment as
a repeated measure of fracture-healing rather than subjecting a
patient to the adverse effects of radiography. Important func-
tional end points also include weight-bearing, pain on palpa-
tion or on weight-bearing, and time to return to work. Clear
rules regarding validity and reliability exist that should help in
the choice of an appropriate patient self-assessment instru-
ment67. Only functional instruments that are validated for the
particular fracture site should be used.
In July 2005, the CHMP provided guidance on patient-
reported outcomes69. The guidance document indicated that
efficacy end points and health-related quality of life can be co-
primary end points. Alternatively, the hierarchical testing of
end points may be applied.
Therefore, in the clinical evaluation of treatments for
fracture-healing, functional outcomes and complication rates
should be supplemented by radiographic scoring of the
fracture-repair process. If one of the outcome variables is
complication rates during fracture-healing, the expected com-
plications have to be exactly defined prior to the study. An
independent review panel is required for the evaluation and
classification of each recorded complication.
Other information in the CHMP guidance document
may be relevant to the assessment of fracture-healing. The docu-
ment states that both generic and disease-specific tools can be
used. A global claim of health-related quality of life requires
demonstration of robust improvements in all or the most im-
portant and clinically relevant domains of functioning that
impact the patient’s quality of life. Specific claims may be
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sought on a subset of domains of the ICF if prespecified in the
analysis plan. A conceptual framework is needed to justify in-
strument and domain selection, appropriateness, and psy-
chometric properties. The amount of change that is required to
be considered as clinically meaningful needs to be prespecified.
All domains must be reported irrespective of negative or pos-
itive change or no change at all. Generally, validation should be
completed before the health-related quality-of-life instrument
is used in therapeutic confirmatory trials. Finally, the same
study should not be used to validate the instrument and to test
the health-related quality-of-life change.
Conclusions
There is a clear need for guidelines for clinical studies oftherapeutic medicinal products that are targeted at or are
suggested to influence fracture-healing. For each study design,
it should be stated whether reduction of a prospectively defined
complication rate or acceleration of fracture-healing is the
primary study goal. Outcome variables should include ob-
jective as well as subjective parameters. The guidelines should
be harmonized between European and American regulatory
authorities to ensure comparability of results of studies. n
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